A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

NCT04009460 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's clinical development strategy adjustment

Conditions

Solid Tumors
Neoplasms
Malignant Tumor

Interventions

DRUG: ES101

Sponsor

Elpiscience Biopharma, Ltd.